New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland

Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional ret...

Ausführliche Beschreibung